The company's supervisory board was due to discuss and vote on the
settlement, which includes a $2 billion buffer for future claims, in
the coming days, paper cited company and negotiating partner sources
as saying.
A spokesman for Bayer declined to comment on the report. Perry Weitz
of Weitz & Luxenberg, one of the leading plaintiffs' firms involved
in the Roundup litigation, also would not comment.
![](http://archives.lincolndailynews.com/2020/Jun/23/images/ads/current/cca_laptop-sda021709.png)
The drugs and pesticides group, which said in May that talks were
progressing, is keen to draw a line under the legal dispute, which
it inherited via its $63 billion takeover of Monsanto in 2018.
[to top of second column] |
![](http://archives.lincolndailynews.com/2020/Jun/23/images/ads/current/graue_sda_2016.png)
In April, Bayer's management regained shareholder support for its handling of
the litigation process.
Bayer's shares rose 5.7% to 72.52 euros at 1045 GMT.
Bayer said in April it has been served with cases in court from 52,500 U.S.
plaintiffs who blame Roundup and other glyphosate-based weedkillers for their
cancer, up from 48,600 in February.
(Reporting by Ludwig Burger, Madeline Chambers and Patricia Weiss; editing by
Thomas Seythal and Louise Heavens)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |